French biotech Client issues Contract Extension based on progress and term sheet discussions

Published : 10 Sep 2021

Aagami’s French biotech client developing a blockbuster potential smoking cessation drug has extended contract with Aagami based on progress and term sheet discussions.

 

Aagami will also be representing the client in BioPharm America 2021 (Sep) and Bio-Europe 2021 (Oct).

 

Aagami team are committed to support the client and to turn discussions into deals.

×
Twitter